A new ADHD drug just got FDA approval. Here's what makes it different.
The Food and Drug Administration (FDA) just approved Simtriyo (centanafadine), a new norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant. The medication treats ADHD in adults, teens, and children ages 6 and up weighing at least 44 pounds.
← Back to stories
2 articles from 2 sources across the spectrum· Updated 65d ago
1 across the spectrum · tap a section to jump
Left
0 viewpointsNo Left coverage yet.
A blind spot on this side of the story.
Center
1 viewpointRan by 2 outlets· KRDO, Wyoming Tribune Eagle
Right
0 viewpointsNo Right coverage yet.
A blind spot on this side of the story.